Pegloticase + Methotrexate
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled Gout
Conditions
Uncontrolled Gout
Trial Timeline
Feb 9, 2026 → Jul 18, 2028
NCT ID
NCT07388498About Pegloticase + Methotrexate
Pegloticase + Methotrexate is a phase 3 stage product being developed by Amgen for Uncontrolled Gout. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07388498. Target conditions include Uncontrolled Gout.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07388498 | Phase 3 | Recruiting |
| NCT06229145 | Approved | Active |
Competing Products
17 competing products in Uncontrolled Gout
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 52 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 33 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 52 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase | Amgen | Approved | 84 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase with MTX | Amgen | Approved | 84 |
| abrocitinib | Pfizer | Pre-clinical | 22 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 32 |